Literature DB >> 30201270

Kill 'Em All: Efgartigimod Immunotherapy for Autoimmune Diseases.

Jagadeesh Bayry1, Srini V Kaveri2.   

Abstract

Neonatal Fc receptors (FcRns) recycle IgGs by preventing their lysosome degradation. As this process also enhances half-life of pathogenic auto-IgG, inspired from the mechanisms of intravenous immunoglobulin, several inhibitors of IgG-FcRn interface have been conceived for treating autoimmune diseases. Among them, the high-affinity FcRn-binding engineered Fc molecule efgartigimod has recently completed phase I clinical trial.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Abdegs; Fc-domain; Seldegs; autoimmunity; circulating normal IgG; intravenous immunoglobulin

Mesh：

Substances：

Year:  2018        PMID： 30201270     DOI： 10.1016/j.tips.2018.08.004

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  3 in total

1.  Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages.

Authors:  Chaitrali Saha; Prathap Kothapalli; Veerupaxagouda Patil; Gundallahalli Bayyappa ManjunathaReddy; Srini V Kaveri; Jagadeesh Bayry
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

Review 2.  The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors.

Authors:  Marinos C Dalakas; Peter J Spaeth
Journal:  Ther Adv Neurol Disord       Date:  2021-02-26       Impact factor: 6.570

3.  The Dual Targeting of FcRn and FcγRs via Monomeric Fc Fragments Results in Strong Inhibition of IgG-Dependent Autoimmune Pathologies.

Authors:  Céline Monnet; Emilie Jacque; Christophe de Romeuf; Alexandre Fontayne; Toufik Abache; Nathalie Fournier; Gilles Dupont; Delphine Derache; Anais Engrand; Aurélie Bauduin; Aurélie Terrier; Alexander Seifert; Cécile Beghin; Alain Longue; Nicholas Masiello; Laetitia Danino; Michel Nogre; Anais Raia; Frederic Dhainaut; Louis Fauconnier; Dieudonnée Togbe; Carmen Reitinger; Falk Nimmerjahn; Wil Stevens; Sami Chtourou; Philippe Mondon
Journal:  Front Immunol       Date:  2021-08-26       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.